Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
Platelet-derived growth factor pathway inhibitors in ovarian cancer
Jordan Schmitt,
Daniela Matei
*
*
Corresponding author for this work
Medicine, Hematology Oncology Division
Research output
:
Contribution to journal
›
Article
›
peer-review
8
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Platelet-derived growth factor pathway inhibitors in ovarian cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Ovarian Cancer
100%
Platelet-derived Growth Factor Receptor (PDGFR)
100%
Platelet-derived Growth factor-BB (PDGF-BB)
100%
Pathway Inhibitors
100%
Growth Factor Pathway
100%
Pericytes
40%
Clinical Trials
20%
Tumor Cells
20%
Angiogenesis
20%
Chemotherapy
20%
Endothelial Cells
20%
Tumor
20%
Sorafenib
20%
Inhibitory Effect
20%
Fibroblast Cells
20%
Tumor Cell Proliferation
20%
Ovarian Tumor
20%
Interstitial Pressure
20%
Paracrine
20%
Cancer Cell Survival
20%
Cancer Therapeutic Agents
20%
Early Clinical Development
20%
Control Tissue
20%
Cancer Cell Proliferation
20%
Dasatinib
20%
Molecular Predictors
20%
Imatinib Mesylate
20%
Sunitinib
20%
Antiangiogenic Properties
20%
Recurrent Ovarian Cancer
20%
Platelet-activating Factor Receptor Antagonist
20%
Medicine and Dentistry
Ovarian Cancer
100%
Platelet Derived Growth Factor Receptor
100%
Platelet Derived Growth Factor
100%
Stroma
50%
Pericyte
33%
Neoplasm
16%
Receptor Antibody
16%
Tumor Progression
16%
Angiogenesis
16%
Therapeutic Agent
16%
Tumor Cell
16%
Cell Proliferation
16%
Endothelial Cell
16%
Cancer Cell
16%
Cell Survival
16%
Malignant Neoplasm
16%
Imatinib
16%
Antiangiogenic
16%
Sorafenib
16%
Sunitinib
16%
Ovarian Tumor
16%
Recurrent Ovarian Cancer
16%
Clinical Trial
16%
Dasatinib
16%
Fibroblast
16%